{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:48:41Z","timestamp":1754153321563,"version":"3.41.2"},"reference-count":17,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]},{"name":"Small\/Large Cell Carcinoma of the Cervix: Sisters United"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1136\/ijgc-2022-003946","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T23:42:15Z","timestamp":1671147735000},"page":"1469-1474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced stage (FIGO IVB) neuroendocrine cervical carcinoma"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct05063916","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-1778","authenticated-orcid":false,"given":"Gloria","family":"Salvo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preetha","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-2648","authenticated-orcid":false,"given":"Michael","family":"Frumovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003946_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2021.04.039","article-title":"Neuroendocrine tumors of the gynecologic tract update","volume":"162","author":"Winer","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0015","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1097\/IGC.0000000000000262","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix","volume":"24","author":"Satoh","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003946_bb0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/ijgc-2019-000504","article-title":"Updates and management algorithm for neuroendocrine tumors of the uterine cervix","volume":"29","author":"Salvo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003946_bb0025","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003946_bb0030","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003946_bb0035","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0040","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2022.03.022","article-title":"Definitive pelvic radiation therapy improves survival in stage IVb neuroendocrine cervical carcinoma: a NeCTuR study","volume":"165","author":"Salvo","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0045","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0050","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ijgc-2020-001649","article-title":"Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix","volume":"30","author":"Carroll","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003946_bb0055","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2016.04.001","article-title":"Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer","volume":"141","author":"Frumovitz","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.10.040","article-title":"Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix","volume":"144","author":"Frumovitz","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0065","article-title":"Unique genomic landscape of high-grade neuroendocrine cervical carcinoma: implications for rethinking current treatment paradigms","volume":"4","author":"Eskander","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gore.2014.09.003","article-title":"Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation","volume":"10","author":"Lyons","year":"2014","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2022-003946_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-017-0038-9","article-title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","volume":"4","author":"Paraghamian","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1136\/ijgc-2022-003946_bb0080","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003946_bb0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/AOG.0000000000004573","article-title":"Complete response to combination nivolumab and ipilimumab in recurrent neuroendocrine carcinoma of the cervix","volume":"138","author":"Paterniti","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003946_bb0090","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:39:33Z","timestamp":1753223973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24007266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1048891X24007266"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003946","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced stage (FIGO IVB) neuroendocrine cervical carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}